

FOI – 1873

4<sup>th</sup> September 2023

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1 – How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?  
*Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.***

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)	12	8	0	15	16	4
Adalimumab (Biosimilars)	195	120	57	169	146	152
Apremilast	0			0		
Bimekizumab	0					
Brodalumab	9					
Certolizumab Pegol	6			27	25	19
Deucravacitinib	0					
Etanercept (Enbrel)	1			4	1	9
Etanercept (Biosimilars)	2			64	26	89
Guselkumab	62			3		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	3	42	51	7	10	8
Ixekizumab	92			30	10	
Risankizumab	53	0		0		
Secukinumab	26			76	51	
Tildrakizumab	9					
Ustekinumab	28	75	29	0		
Upadacitinib		0	1	1	3	11
Vedolizumab		41	59			
Filgotinib			0			0
Golimumab			1	24	33	21
Mirikizumab			0			
Ozanimod			0			
Tofacitinib			5	5	0	7
Abatacept						91
Baricitinib						55
Rituximab						93
Sarilumab						11
Tocilizumab						23

**Q2 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023?**

***Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.***

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	36	8	37
Adalimumab (Biosimilars)	236	177	486
Apremilast	0	0	1

Bimekizumab	0	0	0
Brodalumab	9	0	0
Certolizumab Pegol	6	1	72
Deucravacitinib	0	0	0
Etanercept (Enbrel)	1	0	15
Etanercept (Biosimilars)	2	0	185
Guselkumab	62	0	3
Infliximab (Remicade)	0	0	1
Infliximab (Biosimilars)	7	93	27
Ixekizumab	92	0	40
Risankizumab	53	0	0
Secukinumab	28	0	128
Tildrakizumab	9	0	0
Ustekinumab	28	104	0
Upadacitinib	7	1	16
Vedolizumab	0	100	0
Filgotinib	0	0	0
Golimumab	0	1	77
Mirikizumab	0	0	0
Ozanimod	0	0	0
Tofacitinib	0	5	12
Abatacept	0	0	92
Baricitinib	2	0	56
Rituximab	0	0	121
Sarilumab	0	0	10
Tocilizumab	0	0	42

Email: [Foi.team@southerntrust.hscni.net](mailto:Foi.team@southerntrust.hscni.net)